AACR Annual Meeting

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer (TNBC).

A prospective study of retrospectively analyzed blood samples of patients with nonresectable pancreatic cancer found that plasma KRAS mutational burden correlates with overall survival (OS).

Mark Erlander, PhD, Chief Scientific Officer, Trovagene, discusses a study looking at the association between ctDNA KRAS mutation levels and outcomes in patients with non-resectable pancreatic cancer.

Pembrolizumab (Keytruda) achieved an overall response rate (ORR) of 45.2% among a cohort of patients with high PD-L1-expressing non–small cell lung cancer (NSCLC) in the phase I KEYNOTE-001 trial.

Pembrolizumab (Keytruda) yielded significantly better outcomes compared with ipilimumab (Yervoy) in a randomized phase III trial of patients with advanced melanoma.

IMCgp100, an anti-CD3 antibody fragment fused to a gp100-specific T cell receptor, yielded long-lasting responses in patients with advanced melanoma.